Enrique Grande: Acknowledging Grupo GETNE’s contribution to neuroendocrine tumors

Enrique Grande shared on X:

“Maybe we should stop one day to think and acknowledge the contribution of Grupo GETNE to the progress in neuroendocrine tumors. Great publication in Nature Communications led by Garcia-Carbonero’s Lab. I, personally, had the good fortune to treat the patient who achieved a complete response and despite the devastating initial prognosis, the patient is still alive and without relapse of the disease more than 5 years later. A small step to see that the cure is far away but not impossible.

‘Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).’”

Source: Enrique Grande/X

Enrique Grande, MD, PhD, MSc, is the Director of the Medical Oncology Program and Clinical Research lead at MD Anderson Cancer Center Madrid. Dr. Grande specializes in researching genitourinary and endocrine tumors and actively collaborates in developing the Translational Research and Early Drug Development Unit.

He founded the Spanish Group for Research on Orphan and Uncommon Tumors (GETHI) and serves on the Directory Board of the Spanish Task Force Group for NETs (GETNE). Dr. Grande edits several international journals and has participated in recent neuroendocrine tumor trials that led to the approval of new drugs in this field.